ESC Premium Access

New developments in anti thrombotic drug therapy

Event: ESC CONGRESS 2019
Topic: Antiplatelet Drugs
Session type: Advances in Science
Date: 1 September 2019
Time: 16:40 - 17:50

Session

4 presentations in this session

State of the Art - Novel targets in anti thrombotic drug development

Speaker: Associate Professor B. Rocca (Rome, IT)
Thumbnail

Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin

Speaker: Assistant Professor C. Koh (Singapore, SG)
Thumbnail

Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients

Speaker: Professor R. Storey (Sheffield, GB)
Thumbnail

Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452

Speaker: Professor L. Jennings (Memphis, US)
Thumbnail

4 speakers from this session

Associate Professor Bianca Rocca

Catholic University School of Medicine, Rome (Italy)
7 presentations
0 follower

Assistant Professor Cho Yeow Koh

National University of Singapore, Singapore (Singapore)
0 follower

Professor Robert Storey

Department of Cardiovascular Science, University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)
17 presentations
1 follower

Professor Lisa Jennings

MLM Medical Labs, LLC, Memphis (United States of America)
0 follower

This platform is supported by

logo Novo Nordisk